SPP1 and breast cancer: Osteopontin variants have been associated with outcome (survival or recurrence) in breast cancer [15–18, 30–32], gastric cancer [33], glioma [19], lung cancer [37], mesothelioma [34], pancreatic cancer [35], and soft tissue sarcoma [36].